279 related articles for article (PubMed ID: 25724527)
41. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J
ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760
[TBL] [Abstract][Full Text] [Related]
42. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
[TBL] [Abstract][Full Text] [Related]
43. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
Doi T; Lee KH; Kim TM; Ohtsu A; Kim TY; Ikeda M; Yoh K; Gallo Stampino C; Hirohashi T; Suzuki A; Fujii Y; Andrew Williams J; Bang YJ
Cancer Med; 2016 Jul; 5(7):1454-63. PubMed ID: 27075560
[TBL] [Abstract][Full Text] [Related]
44. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
[TBL] [Abstract][Full Text] [Related]
45. Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Yu T; Liu X; Wu CY; Tang Z; Wang H; Schnell P; Wan Y; Wang K; Liu L; Gao Y; Sahasranaman S; Budha N
Clin Transl Sci; 2024 Mar; 17(3):e13769. PubMed ID: 38515348
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
[No Abstract] [Full Text] [Related]
48. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
49. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
[TBL] [Abstract][Full Text] [Related]
50. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Tolcher AW; Berlin JD; Cosaert J; Kauh J; Chan E; Piha-Paul SA; Amaya A; Tang S; Driscoll K; Kimbung R; Kambhampati SR; Gueorguieva I; Hong DS
Cancer Chemother Pharmacol; 2017 Apr; 79(4):673-680. PubMed ID: 28280971
[TBL] [Abstract][Full Text] [Related]
51. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E; Moreno V; Morgensztern D; Curigliano G; Rutkowski P; Trigo JM; Calvo A; Kowalski D; Cortinovis D; Plummer R; Maio M; Ascierto PA; Vladimirov VI; Cervantes A; Zudaire E; Hazra A; T'jollyn H; Bandyopadhyay N; Greger JG; Attiyeh E; Xie H; Calvo E
Cancer Chemother Pharmacol; 2022 Apr; 89(4):499-514. PubMed ID: 35298698
[TBL] [Abstract][Full Text] [Related]
52. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Sharma S; de Vries EG; Infante JR; Oldenhuis CN; Gietema JA; Yang L; Bilic S; Parker K; Goldbrunner M; Scott JW; Burris HA
Invest New Drugs; 2014 Feb; 32(1):135-44. PubMed ID: 23589214
[TBL] [Abstract][Full Text] [Related]
53. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
54. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract][Full Text] [Related]
55. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
56. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
57. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
58. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
59. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B; Witteveen PO; Ruijter R; Giaccone G; Dontabhaktuni A; Fox F; Katz T; Youssoufian H; Zhu J; Rowinsky EK; Voest EE
Clin Cancer Res; 2010 Mar; 16(6):1915-23. PubMed ID: 20197484
[TBL] [Abstract][Full Text] [Related]
60. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
